Current Oncology Reports

, Volume 9, Issue 4, pp 241–246 | Cite as

Vaccine therapy in non—small-cell lung cancer

  • Carol AlbrightEmail author
  • Jennifer Garst


Lung cancer is the leading cause of death from cancer worldwide. First-line therapy is based on stage at diagnosis can include chemotherapy, radiation, and surgery. Despite advances, the prognosis for advanced-stage lung cancer is very poor. Vaccines with the capability to activate the host immune system may have a role in second-line therapy. Advances in the understanding of cellular and molecular immunology are forming the basis for improving vaccine therapy. Most trials to date have demonstrated safety but inconsistent efficacy. Further research is needed to enhance this potential.


MUC1 Mucin Vaccine Site Logous Tumor Cell Ogous Tumor Quamous Cell Carcinom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    National Cancer Institute. Available at Accessed February 2007.
  2. 2.
    Travis WD, Colby TV, Corrin B, et al.: Histological Typing of Lung and Pleural Tumours, edn 3. Berlin: Springer-Verlag; 1999.Google Scholar
  3. 3.
    Cranmer LD, Trevor KT, Hersh EM: Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol immunother 2004, 53:275–306.PubMedCrossRefGoogle Scholar
  4. 4.
    Chang GC, Lan HC, Juang SH, et al.: A pilot dinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancar 2005, 103:763–771.PubMedCrossRefGoogle Scholar
  5. 5.
    Hirschowitz EA, Foody T, Kryscio R, et al.: Autologous dendritic cell vaccines for non—small-cell lung cancer. J Clin Oncol 2004, 22:2808–2815.PubMedCrossRefGoogle Scholar
  6. 6.
    Yannelli JR, Sturgill J, Foody T, et al.: The largescale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2005, 47:337–350.PubMedCrossRefGoogle Scholar
  7. 7.
    Hammarstrom S: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999, 9:67–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Itoh T, Ueda Y, Kawashima I, et al.: Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002, 51:99–106.PubMedCrossRefGoogle Scholar
  9. 9.
    Ueda Y, Itoh T, Nukaya I, et al.: Dendritic cell-based immunotherapy of cancer with carcinoem bryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 2004, 24:909–917.PubMedGoogle Scholar
  10. 10.
    Morse MA, Clay TM, Hobeika AC, et al.: Phase I study of immunization with dendritic cells modified with Fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005, 11:3017–3024.PubMedCrossRefGoogle Scholar
  11. 11.
    Rusch V, Baselga J, Cordon-Cardo C, et al.: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53:2379–2385.PubMedGoogle Scholar
  12. 12.
    Gonzalez G, Crombet T, Catala M, et al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann Oncol 1998, 9:431–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Gonzalez G, Crombet T, Torres F, et al.: Epidermal growth factor-based cancer vaccine for non—small-cell lung cancer therapy. Ann Oncol 2003, 14:461–466.PubMedCrossRefGoogle Scholar
  14. 14.
    Ramos TC, Vinageras EN, Ferrer MC, et al.: Treatment of NSCLC patients with and EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther 2006, 5:145–149.PubMedCrossRefGoogle Scholar
  15. 15.
    Uchida N, Otsuka T, Shigematsu H, et al.: Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res 1999, 23:1127–1132.PubMedCrossRefGoogle Scholar
  16. 16.
    Tahara H, Yasui W, Tahara E, et al.: Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumour and non-tumour tissue sections. Oncogene 1999, 18:1561–1567.PubMedCrossRefGoogle Scholar
  17. 17.
    Fujita Y, Fujikane T, Fujiuchi S, et al.: The diagnostic and prognostic relevance of human an telomerase reverse transcriptase mRNA expression detected in situ in patients with non-small cell lung carcinoma. Cancer 2003, 298:1008–1013.CrossRefGoogle Scholar
  18. 18.
    Brunsvig PF, Aamdal S, Gjertsen MK, et al.: Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006, 55:1553–1564.PubMedCrossRefGoogle Scholar
  19. 19.
    Kotani K, Taguchi O, Narita T, et al.: Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 2001, 84:1258–1264.CrossRefGoogle Scholar
  20. 20.
    Rochlitz C, Figlin R, Squiban P, et al.: Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003, 5:690–699.PubMedCrossRefGoogle Scholar
  21. 21.
    Kontani K, Taguchi O, Ozaki Y, et al.: Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 2003, 12:493–502.PubMedGoogle Scholar
  22. 22.
    Palmer M, Parker J, Modi S, et al.: Phase I study of the BLP25 (MUC1 peptide) lisosomal vaccine for active specific immunotherapy in stage IIIB/IV non—small-cell lung cancer (NSCLC). Clin Lung Cancer 2001, 3:49–57.PubMedCrossRefGoogle Scholar
  23. 23.
    Butts C, Murray N, Maksymiuk A, et al.: Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non—small-cell lung cancer. J Clin Oncol 2005, 23:6674–6681.PubMedCrossRefGoogle Scholar
  24. 24.
    Van den Eynde BJ, van der Bruggen P: T cell defined tumour antigens. Curr Opin Immunol 1997, 9:684–693.PubMedCrossRefGoogle Scholar
  25. 25.
    Atanackovic D, Altorki NKI, Stockert E, et al.: Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004, 172:3289–3296.PubMedGoogle Scholar
  26. 26.
    Denzer K, Kleijmeer MJ, Heijnen HF, et al.: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000, 113:3365–3374.PubMedGoogle Scholar
  27. 27.
    Thery C, Duban L, Segura E, et al.: Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002, 3:1156–1162.PubMedCrossRefGoogle Scholar
  28. 28.
    Andre F, Chaput N, Schartz, NEC, et al.: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004, 172:2126–2136.PubMedGoogle Scholar
  29. 29.
    Morse MA, Garst J, Osada T, et al.: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005, 3:9–16.PubMedCrossRefGoogle Scholar
  30. 30.
    Mueller-Pillasch F, Pohl B, Wilda M, et al.: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999, 88:95–99.PubMedCrossRefGoogle Scholar
  31. 31.
    Nemunaitis J, Meyers T, Senzer N, et al.: Phase I trial of sequential administration of recombinant DNA and adenoviral expressing L523S protein in early stage non small cell lung cancer (NSCLC). Mol Ther 2006, 13:1185–1191.PubMedCrossRefGoogle Scholar
  32. 32.
    Raez LE, Cassileth PA, Schlesselman JJ, et al.: Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinom a cell line in patients with advanced non—small-cell lung cancer. J Clin Oncol 2004, 22:2800–2807.PubMedCrossRefGoogle Scholar
  33. 33.
    Scheffer SR, Nave H, Korangy F, et al.: Apoptotic but not necrotic tumour cell vaccines induce a potent, specific, and long-lasting antitum our immunity. Proc Natl Acad Sci U S A 1993, 90:3539–3543.CrossRefGoogle Scholar
  34. 34.
    Salgia R, Lynch T, Skarin A, et al.: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulation factor augments antitumor immunity in some patients with metastatic non—small-cell lung carcinoma. J Clin Oncol 2003, 21:624–630.PubMedCrossRefGoogle Scholar
  35. 35.
    Nemunaitis J, Sterman D, Jablons D, et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non—small-cell lung cancer. J Natl Cancer Inst 2004, 96:326–331.PubMedCrossRefGoogle Scholar
  36. 36.
    Nemunaitis J, Jahan T, Ross H, et al.: Phase ½ trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non—small-cell lung cancer. Cancer Gene Ther 2006, 13:555–562.PubMedCrossRefGoogle Scholar
  37. 37.
    Jakowlew SB, Mathias A, Chung P, et al.: Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 1995, 6:465–476.PubMedGoogle Scholar
  38. 38.
    Kong F, Jirtle RL, Huang DH, et al.: Plasma transforming growth factor-beta1 level before radiotherapy correlates with long-term outcome of patients with lung carcinoma. Cancer 1999, 86:1712–1719.PubMedCrossRefGoogle Scholar
  39. 39.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, et al.: Phase II study of Belagenpum atucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non—small-cell lung cancer. J Clin Oncol 2006, 24:4721–4730.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Department of MedicineDuke University Medical CenterDurhamUSA

Personalised recommendations